Rosuvastatin is Superior to Lovastatin for Elderly Patients
For an elderly patient concerned about cognitive effects, rosuvastatin is the preferred choice over lovastatin due to its significantly greater LDL-C lowering potency (43-63% vs 20-30%), once-daily dosing convenience, fewer drug interactions, and no evidence of increased cognitive harm. 123
LDL-C Lowering Potency: Rosuvastatin Wins Decisively
The potency difference is substantial and clinically meaningful:
According to the 2026 ACC/AHA guidelines, rosuvastatin 20-40 mg qualifies as high-intensity statin therapy (≥50% LDL-C reduction), while lovastatin at any dose is classified as moderate- to low-intensity therapy 1. In elderly patients specifically, rosuvastatin demonstrated a 35.8% LDL-C reduction compared to lovastatin's 22.5% reduction in real-world practice 4. This translates to 93.6% of elderly patients reaching NCEP ATP III goals on rosuvastatin versus only 66.8% on lovastatin 4.
Dosing Regimen: Simpler with Rosuvastatin
- Rosuvastatin: Once daily, any time of day, starting dose 10 mg 2
- Lovastatin: Must be taken with evening meal for optimal absorption; starting dose 20 mg 3
The meal requirement for lovastatin adds complexity that may reduce adherence in elderly patients managing multiple medications.
Renal Dose Adjustments: Critical Difference
Rosuvastatin requires dose adjustment in severe renal impairment (start 5 mg if CrCl <30 mL/min) 2, while lovastatin requires caution but less specific adjustment 3. However, rosuvastatin has been specifically studied and shown efficacy in patients with renal impairment 5, making it actually safer when properly dosed.
Drug Interaction Potential: Rosuvastatin Has the Edge
This is particularly important for elderly patients on polypharmacy:
Rosuvastatin is NOT metabolized by CYP3A4, resulting in fewer clinically significant drug interactions 265. Lovastatin IS extensively metabolized by CYP3A4 3, creating dangerous interactions with:
- Azole antifungals (ketoconazole, itraconazole)
- Macrolide antibiotics (erythromycin, clarithromycin)
- HIV protease inhibitors
- Grapefruit juice
- Amiodarone, verapamil, diltiazem
The 2026 ACC/AHA guidelines specifically note that drug-drug interactions are statin-specific, and a clinician tool is available to manage these 1. For elderly patients typically on 5+ medications, rosuvastatin's cleaner interaction profile is a significant safety advantage.
Cognitive Safety: No Evidence of Harm with Either
Current evidence does not support cognitive concerns as a reason to avoid either statin in elderly patients. The most recent comprehensive review (2026) analyzing over 100,000 individuals found no causal effect of statins on dementia or cognitive decline 7.
Key cognitive safety findings:
- Most RCTs show no harmful cognitive effects from statins 78
- Some observational data suggest possible protective effects 78
- The 2013 ACC/AHA guidelines stated "no evidence supports that statins cause adverse effects on cognition" 9
- One small 2021 study (n=29) suggested LDL-C <70 mg/dL might correlate with cognitive impairment 10, but this is not sufficient to change practice and may reflect reverse causation
For patients with pre-existing cognitive impairment, if cognitive concerns persist despite counseling, consider:
- Hydrophilic statins (rosuvastatin, pravastatin) may theoretically be safer than lipophilic ones (lovastatin, simvastatin, atorvastatin) due to reduced blood-brain barrier penetration 10
- This makes rosuvastatin the preferred choice if cognitive safety is the primary concern
Clinical Algorithm for Elderly Patients
Start rosuvastatin 10 mg once daily for most elderly patients. This provides:
- High-intensity LDL-C lowering without titration
- Minimal drug interactions
- No meal timing requirements
- Established safety in elderly populations 5
Use rosuvastatin 5 mg if:
- Severe renal impairment (CrCl <30 mL/min)
- Asian ancestry (higher drug exposure)
- Concurrent cyclosporine use
Avoid lovastatin in elderly patients taking CYP3A4 inhibitors or those requiring high-intensity statin therapy.
Important Caveats
The 2020 JAGS guideline review notes that advanced age (≥65 years) is a predisposing factor for myopathy 113. Both statins require caution, but this is not a reason to choose lovastatin over rosuvastatin. Monitor for:
- Unexplained muscle pain, tenderness, or weakness
- Baseline and follow-up CK if symptomatic
- Baseline and periodic LFTs
The ongoing PREVENTABLE and STAREE trials will provide definitive cognitive outcome data in older adults 7, but current evidence strongly supports continuing statin therapy for cardiovascular benefit without cognitive safety concerns.